PerkinElmer (PKI) stock is expected to deviate a maximum of $2.97 from the average target price of $56.8 for the short term period. 10 Street Experts have initiated coverage on the stock with the most promising target being $61 and the most muted being $52.
PerkinElmer (PKI) : 12 analysts are covering PerkinElmer (PKI) and their average rating on the stock is 2.54, which is read as a Hold. 3 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. PerkinElmer (PKI) also receives 1 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. However, 1 analysts consider that the stock has more downward risks ahead, hence, they suggest a Strong Sell on the stock. A total of 7 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Also, Equity Analysts at the Mizuho Securities downgrades the rating on PerkinElmer (NYSE:PKI). The brokerage firm has issued a Neutral rating on the shares. The shares were previously rated Buy. The rating by the firm was issued on August 5, 2016.
PerkinElmer (NYSE:PKI): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $53.27 and $52.99 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $53.53. The buying momentum continued till the end and the stock did not give up its gains. It closed at $53.26, notching a gain of 0.02% for the day. The total traded volume was 489,953 . The stock had closed at $53.25 on the previous day.
PerkinElmer, Inc. is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates its business in two segments: Human Health and Environmental Health. The Companys Human Health segment concentrates on developing diagnostics, tools and applications to help detect diseases earlier and more accurately, and to accelerate the discovery and development of new therapies. The Companys Environmental Health segment provides products, services and solutions to facilitate the creation of safer food and consumer products, more secure surroundings and efficient energy resources. The Company markets its products and services in more than 150 countries.